menu
    • menu
    [{"orgOrder":0,"company":"Jaguar Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Maltodextrin","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Gel","sponsorNew":"Jaguar Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Inapplicable"},{"orgOrder":0,"company":"Venture Life","sponsor":"Jaguar Health","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Maltodextrin","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Venture Life","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Gel","sponsorNew":"Venture Life \/ Jaguar Health","highestDevelopmentStatusID":"15","companyTruncated":"Venture Life \/ Jaguar Health"}]

    Find Clinical Drug Pipeline Developments & Deals for Dextrin

    Menu

    Dextrin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Jaguar Health

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            Jaguar Health

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Maltodextrin

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Jaguar Health Launches Oral Mucositis Product Gelclair in U.S.

                            Details : Gelclair (maltodextrin) is indicated to alleviate pain by adhering to the mucosal surface of the mouth and treating oral lesions, including oral mucositis/stomatitis.

                            Product Name : Gelclair

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 16, 2024

                            Lead Product(s) : Maltodextrin

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Venture Life

                            United Kingdom arrow
                            World Vaccine Conference
                            Not Confirmed

                            Venture Life

                            United Kingdom arrow
                            World Vaccine Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Maltodextrin

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved FDF

                            Sponsor : Jaguar Health

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Jaguar Licenses Oral Mucositis Product for U.S. Market in Cancer Care

                            Details : Gelclair will be commercialized by Jaguar Health in the U.S. to alleviate pain from oral lesions, including mucositis and stomatitis.

                            Product Name : Gelclair

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            April 16, 2024

                            Lead Product(s) : Maltodextrin

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved FDF

                            Sponsor : Jaguar Health

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth